Savient’s Puricase PDUFA date (correction)
Executive Summary
The FDA action date for Savient's Puricase (pegloticase) for gout is April 30, 2009; "The Pink Sheet" incorrectly reported the date (1"The Pink Sheet," Feb. 2, 2009, In Brief)
You may also be interested in...
FDA panel to weigh Savient’s Puricase for gout
FDA's Arthritis Drugs Advisory Committee will evaluate the BLA for Savient Pharmaceutical's Puricase (pegloticase) for the orphan indication of treatment-failure gout. Under priority review, the product's action date is April 20 1("The Pink Sheet" DAILY, Dec. 29, 2008). Late last year, the panel unanimously recommended Takeda's gout therapy febuxostat (2"The Pink Sheet" DAILY, Nov. 24, 2008)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.